Medical Information Only. Always consult your healthcare provider before enrolling in any clinical trial.
NCT07427017 · ClinicalTrials.gov registry record · Phase 2
Selenium Supplementation in Moderate-Severely Active Ulcerative Colitis Patients Treated With Advanced Therapies
A Phase 2 study of Ulcerative Colitis (UC), sponsored by Northwestern University.
- Recruiting
- Registry status
- Phase 2
- Development phase
- 180
- Enrollment target
- 1
- Study location
NCT07427017 is a Phase 2 study of Ulcerative Colitis (UC) that is actively recruiting participants, run by Northwestern University. The registered enrollment target is 180 participants, below the 754-participant average among 17 other Ulcerative Colitis (UC) trials with a reported enrollment target (76% lower). The trial reports 1 study location across 1 state.
The verdict
NCT07427017, a Phase 2 study of Ulcerative Colitis (UC), is actively recruiting participants, sponsored by Northwestern University.
- RECRUITING
- Registry status
- Phase 2
- Development phase
- 180 participants
- Enrollment target
- 1
- Study location
Study Summary
Micronutrient deficiencies are common in ulcerative colitis (UC). Selenium deficiency is associated with worse disease outcomes including disease flares and need for surgery. Previous in vitro and in vivo studies demonstrated that selenium regulates colonic inflammation, and that selenium supplementation protects against DSS-induced colitis. In this proof-of-concept clinical trial, we aim to test the hypothesis that selenium supplementation in moderate to severely active UC patients will improve responsiveness to advanced therapy such as biologics and small molecules.
Conditions Studied
Interventions
- DRUG Placebo
- DRUG Selenium supplementation
Study Locations (1)
Illinois
- Northwestern University - Chicago
Trial Details
| Field | Value |
|---|---|
| Enrollment Target | 180 participants |
| Start Date | 2026-02 |
| Est. Completion | 2028-12 |
| Phase | Phase 2 |
Interested in This Trial?
Full Details on ClinicalTrials.gov ↗What the Registry Record Tells You About NCT07427017
The ClinicalTrials.gov registry entry for NCT07427017 describes a study currently listed as recruiting, categorized as Phase 2. The registered enrollment target is 180 participants, a figure that helps gauge the scale of data the investigators plan to collect, below the 754-participant average among 17 other Ulcerative Colitis (UC) trials with a reported enrollment target (76% lower). The listed sponsor is Northwestern University, which has 1,209 total studies on file at ClinicalTrials.gov.
The record links to 1 condition, with Ulcerative Colitis (UC) appearing as the primary indexed condition, and to 2 interventions - of which Placebo is the first listed.
NCT07427017 reports 1 study location spanning 1 distinct geographic area - top geographies include Illinois.
Frequently Asked Questions
What is clinical trial NCT07427017 about?
NCT07427017 is a clinical study titled "Selenium Supplementation in Moderate-Severely Active Ulcerative Colitis Patients Treated With Advanced Therapies". Micronutrient deficiencies are common in ulcerative colitis (UC). Selenium deficiency is associated with worse disease outcomes including disease flares and need for surgery. Previous in vitro and in vivo studies demonstrated that selenium regulates colonic inflammation, and that selenium supplement...
What is the current status of trial NCT07427017?
This trial is currently recruiting. It is a Phase 2 study. The enrollment target is 180 participants. The study started on 2026-02. Estimated completion is 2028-12.
What conditions does trial NCT07427017 study?
This clinical trial studies the following conditions: Ulcerative Colitis (UC).
What interventions are being tested in trial NCT07427017?
The interventions under investigation include: Placebo (DRUG), Selenium supplementation (DRUG).
Who is sponsoring clinical trial NCT07427017?
This trial is sponsored by Northwestern University, which has 1,209 total clinical trials registered on ClinicalTrials.gov.
Where is trial NCT07427017 being conducted?
This trial has 1 study location across Illinois. Contact the study sites directly through ClinicalTrials.gov for enrollment availability.
Learn More About Clinical Trials
Similar trials for Ulcerative Colitis (UC)
Matched on the same primary condition, ranked to surface studies in the same phase first, then by recruiting status, no relevance scoring or editorial curation.
-
A Phase 2 Study to Evaluate Therapies for Inflammatory Bowel Disease
RECRUITING · Phase 2
-
A Study to Investigate How Well Ravagalimab (ABBV-323) Works and How Safe it is in Participants With Moderate to Severe Ulcerative Colitis Who Failed Prior Therapy
COMPLETED · Phase 2
-
Zymfentra (Infliximab-dyyb) REal World Cohort STudy
RECRUITING
-
Evaluate the Safety, Tolerability, PK and PD of SAD of Intravenously Adminsterted ALTB-268 in Healthy Participants
RECRUITING · Phase 1
-
STOP-UC: De-escalation of Therapy in Patients With Ulcerative Colitis With Histological Remission
RECRUITING · NA
-
Study of XmAb942 in Healthy Participants and Participants With Ulcerative Colitis
RECRUITING · Phase 1
Read our methodology - how this data is sourced, computed, and verified.
Related
Every figure on PlainTrial is rendered directly from the ClinicalTrials.gov registry, no number is typed in by an editor. This page mirrors this trial's own ClinicalTrials.gov registry record, live from the dataset. See our editorial standards & corrections policy, the methodology behind these numbers, or report a data error.